Biogen Inc
BIIB187.620USD
+1.620+0.87%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
27.52BMarket Cap
17.07P/E TTM
More Details of Biogen Inc Company
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Inc Info
Ticker SymbolBIIB
Company nameBiogen Inc
IPO dateSep 17, 1991
CEOViehbacher (Christopher A)
Number of employees7605
Security typeOrdinary Share
Fiscal year-endSep 17
Address225 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone17814642000
Websitehttps://www.biogen.com/
Ticker SymbolBIIB
IPO dateSep 17, 1991
CEOViehbacher (Christopher A)
Company Executives of Biogen Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+20082.00%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+3160.00%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+3921.00%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+167.00%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+2370.00%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-2223.00%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+2370.00%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-517.00%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+2370.00%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+2370.00%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+20082.00%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+3160.00%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+3921.00%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+167.00%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+2370.00%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-2223.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MS product revenues-TYSABRI
827.20M
32.64%
Spinal Muscular Atrophy-SPINRAZA
533.30M
21.04%
MS product revenues-Fumarate
382.80M
15.10%
MS product revenues-Interferon
246.90M
9.74%
Biosimilar product revenues-BENEPALI
121.90M
4.81%
Other
422.60M
16.67%
By RegionUSD
Name
Revenue
Proportion
United States
1.37B
54.18%
Rest of world
911.60M
35.96%
United states-Revenues from anti-CD20 therapeutic
493.90M
19.49%
Rest of World-Other revenues
151.20M
5.97%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MS product revenues-TYSABRI
827.20M
32.64%
Spinal Muscular Atrophy-SPINRAZA
533.30M
21.04%
MS product revenues-Fumarate
382.80M
15.10%
MS product revenues-Interferon
246.90M
9.74%
Biosimilar product revenues-BENEPALI
121.90M
4.81%
Other
422.60M
16.67%
Shareholding Stats
Updated: Sun, Jan 4
Updated: Sun, Jan 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
Other
64.59%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
Other
64.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.76%
Investment Advisor/Hedge Fund
26.60%
Hedge Fund
8.04%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
Other
3.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
2010
137.76M
93.90%
-6.74M
2025Q3
2054
139.52M
98.56%
+3.73M
2025Q2
2076
135.78M
99.30%
-133.40K
2025Q1
2125
136.05M
101.20%
-12.08M
2024Q4
2114
138.28M
98.83%
+2.02M
2024Q3
2089
135.94M
98.13%
+100.43K
2024Q2
2100
135.44M
97.85%
-355.51K
2024Q1
2106
135.99M
97.60%
-5.88M
2023Q4
2136
135.17M
94.89%
+4.09M
2023Q3
2150
131.42M
95.94%
-1.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
17.21M
11.73%
-2.37K
-0.01%
Sep 30, 2025
PRIMECAP Management Company
14.95M
10.19%
-847.42K
-5.36%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
5.6%
+19.35K
+0.24%
Sep 30, 2025
State Street Investment Management (US)
7.32M
4.99%
-149.06K
-2.00%
Sep 30, 2025
Wellington Management Company, LLP
4.25M
2.89%
-551.92K
-11.50%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.07M
2.77%
+150.63K
+3.84%
Sep 30, 2025
Point72 Asset Management, L.P.
3.87M
2.64%
+41.17K
+1.07%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.13M
1.45%
+90.48K
+4.43%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
1.89M
1.29%
+95.29K
+5.32%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
5.49%
First Trust NASDAQ Pharmaceuticals ETF
4.45%
iShares Neuroscience and Healthcare ETF
4.25%
First Trust NYSE Arca Biotechnology Index Fund
3.53%
VanEck Biotech ETF
3.46%
Invesco Pharmaceuticals ETF
3.01%
iShares Health Innovation Active ETF
2.81%
First Trust Health Care Alphadex Fund
2.4%
ProShares Ultra Nasdaq Biotechnology
2.22%
Alger Russell Innovation ETF
2.21%
View more
Invesco Biotechnology & Genome ETF
Proportion5.49%
First Trust NASDAQ Pharmaceuticals ETF
Proportion4.45%
iShares Neuroscience and Healthcare ETF
Proportion4.25%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.53%
VanEck Biotech ETF
Proportion3.46%
Invesco Pharmaceuticals ETF
Proportion3.01%
iShares Health Innovation Active ETF
Proportion2.81%
First Trust Health Care Alphadex Fund
Proportion2.4%
ProShares Ultra Nasdaq Biotechnology
Proportion2.22%
Alger Russell Innovation ETF
Proportion2.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biogen Inc?
The top five shareholders of Biogen Inc are:
The Vanguard Group, Inc. holds 17.21M shares, accounting for 11.73% of the total shares.
PRIMECAP Management Company holds 14.95M shares, accounting for 10.19% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.21M shares, accounting for 5.60% of the total shares.
State Street Investment Management (US) holds 7.32M shares, accounting for 4.99% of the total shares.
Wellington Management Company, LLP holds 4.25M shares, accounting for 2.89% of the total shares.
The Vanguard Group, Inc. holds 17.21M shares, accounting for 11.73% of the total shares.
PRIMECAP Management Company holds 14.95M shares, accounting for 10.19% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.21M shares, accounting for 5.60% of the total shares.
State Street Investment Management (US) holds 7.32M shares, accounting for 4.99% of the total shares.
Wellington Management Company, LLP holds 4.25M shares, accounting for 2.89% of the total shares.
What are the top three shareholder types of Biogen Inc?
The top three shareholder types of Biogen Inc are:
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Biogen Inc (BIIB)?
As of 2025Q4, 2010 institutions hold shares of Biogen Inc, with a combined market value of approximately 137.76M, accounting for 93.90% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.65%.
What is the biggest source of revenue for Biogen Inc?
In FY2025Q3, the MS product revenues-TYSABRI business generated the highest revenue for Biogen Inc, amounting to 827.20M and accounting for 32.64% of total revenue.
